Regarding IL-17 and IL-23 inhibitors, a recent population-based observational study found a lower risk of herpes zoster associated with them than with TNF-α inhibitors, with hazard ratios of 0.58 and 0.79, respectively [35]. Here, IL17A is linked to herpes zoster.